A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
News|Articles|June 24, 2025 (Updated: June 26, 2025)
Q3 2025: 10 FDA Decisions to Watch in the Realm of Oncology
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your Q3 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for sunvozertinib, linvoseltamab, vuslimogene oderparepvec, and more.
Advertisement
Advertisement
As the second quarter of 2025 closes, the pace of oncology innovation shows no signs of slowing. Recent FDA approvals have reinforced the shift toward more targeted, immunologically driven, and personalized therapies across a broad spectrum of cancers.
Related to this article
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
Advertisement
Advertisement